Industry › BioTech

Press Releases

Novotech 收购欧洲 CRO——加强全球运营

Jan 12, 2023 15:00 HKT/SGT

노보텍, 유럽 CRO 인수 - 글로벌 운영 강화

Jan 12, 2023 15:00 HKT/SGT

Novotech Acquires European CRO, Strengthens Global Operations

Jan 12, 2023 15:00 HKT/SGT

Novotech 收購美國藥物開發諮詢公司 CBR International

Jan 12, 2023 15:00 HKT/SGT

Novotech 收購歐洲 CRO——加強全球運營

Jan 12, 2023 15:00 HKT/SGT

아방스 클리니컬, GlobalReady 성공 축하　40개 이상의 생명공학 고객이 프로그램에 참여

Jan 12, 2023 07:00 HKT/SGT

Avance Clinical 慶祝GlobalReady成功　超過40家生物技術客戶進入計劃

Jan 12, 2023 07:00 HKT/SGT

Avance Clinical 庆祝GlobalReady成功　超过40家生物技术客户进入计划

Jan 12, 2023 07:00 HKT/SGT

HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study)

Jan 11, 2023 21:00 HKT/SGT

Avance Clinical Celebrates GlobalReady Success as 40 Biotechs Join Program

Jan 11, 2023 15:00 HKT/SGT

Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe

Jan 11, 2023 11:52 HKT/SGT

Prenetics旗下的行动基因的ACTOnco® IVD产品获得FDA许可成为首家就适用于所有实体肿瘤的癌症基因检测取得许可的亚洲公司

Jan 11, 2023 11:21 HKT/SGT

Prenetics旗下的行動基因的ACTOnco® IVD產品獲得FDA許可成為首家就適用於所有實體腫瘤的癌症基因檢測取得許可的亞洲公司

Jan 11, 2023 11:20 HKT/SGT

Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors

Jan 11, 2023 11:19 HKT/SGT

エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、欧州において早期アルツハイマー病に係る適応で販売承認申請を提出

Jan 11, 2023 09:00 JST

君聖泰HTD1801治療非酒精性脂肪性肝炎（NASH）的臨床IIb 期研究（CENTRICITY研究）完成首例患者給藥

Jan 11, 2023 08:01 HKT/SGT

君圣泰HTD1801治疗非酒精性脂肪性肝炎（NASH）的临床IIb 期研究（CENTRICITY研究）完成首例患者给药

Jan 11, 2023 08:00 HKT/SGT

China Biotech Services subsidiary AMDL nominated as Top Clinical Laboratory Services Company in APAC 2022 and receives CAP Accreditation Certificate

Jan 10, 2023 16:33 HKT/SGT

Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease

Jan 09, 2023 20:55 HKT/SGT

FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

Jan 09, 2023 19:40 HKT/SGT